Crossmark

Biokinetic and dosimetric aspects of 64CuCl2 in human prostate cancer: possible theranostic implications

Crossref DOI link: https://doi.org/10.1186/s13550-018-0373-9

Published Online: 2018-03-01

Published Print: 2018-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Righi, Sergio

Ugolini, Martina

Bottoni, Gianluca

Puntoni, Matteo

Iacozzi, Massimiliano

Paparo, Francesco

Cabria, Manlio

Ceriani, Luca

Gambaro, Monica

Giovanella, Luca

Piccardo, Arnoldo http://orcid.org/0000-0002-6779-1471
License Information

Text and Data Mining valid from 2018-03-01
More Information

Article History

Received: 22 December 2017

Accepted: 20 February 2018

First Online: 1 March 2018

Ethics approval and consent to participate

: This protocol was approved by the Bioethical Committee of “Regione Liguria”. All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. Informed consent was obtained from all individual participants included in the study.

: Not applicable

: The authors declare that they have no competing interest.

: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.